Virtual Conference: AcademyHealth's 2021 Health Datapalooza and National Health Policy Conference
AcademyHealth's 2021 Health Datapalooza and National Health Policy Conference (NHPC) on the data and evidence that will drive innovation and help achieve our goals of better health and health care for everyone.
The Best of Health Data and Health Policy Innovation
NPC was honored to participate Tuesday, February 16 - Thursday, February 18, 2021 at AcademyHealth's 2021 Health Datapalooza and National Health Policy Conference (NHPC) for three days of virtual, boundary-breaking discussions about the latest and most important health policy issues facing our nation. This event focused on the data and evidence that will drive innovation and help achieve our goals of better health and health care for everyone. The National Pharmaceutical Council (NPC) was a sponsor of the conference.
Through a combination of online plenary, breakout, and poster sessions, as well as virtual networking and group activities, the 2021 conference harnessed and strengthened the synergies that exist between the data and policy worlds and offer innovative solutions to directly confront the challenges, opportunities, and threats facing U.S. health care.
On Wednesday, February 17 at 12:30 p.m. - 1:30 p.m., Robert Dubois, MD, PhD, interim president and CEO of NPC, moderated a session, "If the NIH Funds the Research, Should There be a Government Discount?"
Panelists:
- Craig Garthwaite, PhD, Kellogg School of Management at Northwestern University
- Aaron Kesselheim, MD, JD, MPH, Program on Regulation, Therapeutics, and Law, Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital
- Stephen Parente, PhD, MPH, MS, University of Minnesota
Emphasizing economics and practicality, this panel will explore several key questions:
- What is the "value" to taxpayers for National Institutes of Health (NIH)-funded research that translates into early-stage life-sciences products, and should such funding impact pricing?
- How does the COVID pandemic, rapid vaccine development process, and related funding infusion impact economic and societal viewpoints on the core question
- Should NIH funding impact future changes to the patent, licensing, or regulatory pathways?